HU-210 is a
synthetic cannabinoid that was first
synthesized in 1988 from (1R,5S)-
myrtenol[2] by a group led by
Raphael Mechoulam at the
Hebrew University.[3][4][5] HU-210 is 100 to 800 times more potent than natural
THC from
cannabis and has an extended duration of action.[6] HU-210 has a binding affinity of 0.061 nM at CB1 and 0.52 nM at CB2 in cloned human cannabinoid receptors[7] compared to delta-9-THC of 40.7 nM at CB1. [8] HU-210 is the (–)-1,1-dimethylheptyl analog of 11-hydroxy- Δ8- tetrahydrocannabinol; in some references it is called 1,1-dimethylheptyl- 11-hydroxytetrahydrocannabinol. The abbreviation "HU" stands for Hebrew University.
HU-210 has an oral LD50 of 5,000 mg/kg in rats and 14,200 mg/kg in rabbits.[11] HU-210 has an LDLO (Lowest Lethal Dose amount) of 143 mg/kg in humans.[11] Delta-8-THC LD50 has not been confirmed. In a 1973 study monkeys and dogs given 9,000 mg/kg of delta-8-THC was nonlethal.[12][13]
HU-210 is banned in New Zealand as of 8 May 2014.[15]
United States
HU-210 is not explicitly listed in the
list of scheduled controlled substances in the USA.[16] A brief profile of HU-210 written and published by the
Drug Enforcement Administration (DEA) in 2009, but removed in later years, stated that HU-210 is a Schedule I controlled substance under the
Controlled Substances Act due to being similar to
THC.[17] A version of the document (updated in 2013), now in PDF form, exists on the DEA Office of Diversion Control's website.[1] In that PDF, the DEA reasserts that HU-210 is a Schedule I substance. The DEA currently considers HU-210 a Schedule I controlled substance under the umbrella of ‘tetrahydrocannabinols’ under CSCN 7370.[18]
Alabama
HU-210 is a Schedule I controlled substance in
Alabama.[19]
(4)a. A synthetic controlled substance that is any material, mixture, or preparation that contains any quantity of the following chemical compounds, their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation or compound:
...
9. (6aR, 10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol, some trade or other names: HU-210.
(c) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances or that contains any of their salts, isomers, including optical, positional, or geometric isomers, homologues, nitrogen-heterocyclic analogs, esters, ethers, and salts of isomers, homologues, nitrogen-heterocyclic analogs, esters, or ethers, if the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation or class description:
... 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol].
Vermont
Effective January 1, 2016, HU-210 is a regulated drug in Vermont designated as a "Hallucinogenic Drug."[21]
^
ab"HU-210"(PDF). Office of Diversion Control. Drug Enforcement Administration, U.S. Department of Justice. January 2013. Archived from
the original(PDF) on 2016-12-28. 6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol)] [Purported Ingredient of "Spice"
^
abMechoulam R, Lander N, Zahalka J (January 1990). "Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative". Tetrahedron: Asymmetry. 1 (5): 315–318.
doi:
10.1016/S0957-4166(00)86322-3.
^Mechoulam R, Feigenbaum JJ, Lander N, Segal M, Järbe TU, Hiltunen AJ, Consroe P (September 1988). "Enantiomeric cannabinoids: stereospecificity of psychotropic activity". Experientia. 44 (9): 762–4.
doi:
10.1007/BF01959156.
PMID3416993.
S2CID19589995.
^Little PJ, Compton DR, Mechoulam R, Martin BR (March 1989). "Stereochemical effects of 11-OH-delta 8-THC-dimethylheptyl in mice and dogs". Pharmacology, Biochemistry, and Behavior. 32 (3): 661–6.
doi:
10.1016/0091-3057(89)90014-2.
PMID2544901.
S2CID140209484.
^Järbe TU, Hiltunen AJ, Mechoulam R (September 1989). "Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-hydroxy-delta 8-tetrahydrocannabinol in rats and pigeons". The Journal of Pharmacology and Experimental Therapeutics. 250 (3): 1000–5.
PMID2550611.
^Devane WA, Breuer A, Sheskin T, Järbe TU, Eisen MS, Mechoulam R (May 1992). "A novel probe for the cannabinoid receptor". Journal of Medicinal Chemistry. 35 (11): 2065–9.
doi:
10.1021/jm00089a018.
PMID1317925.
^"PART 1308 - Section 1308.11 Schedule I". Office of Diversion Control. Drug Enforcement Administration, U.S. Department of Justice.
Archived from the original on 27 August 2009. Retrieved 3 May 2018.